BR112014015832A8 - derivados heterocíclicos como receptores associados com aminas vistigiais (taars) - Google Patents
derivados heterocíclicos como receptores associados com aminas vistigiais (taars)Info
- Publication number
- BR112014015832A8 BR112014015832A8 BR112014015832A BR112014015832A BR112014015832A8 BR 112014015832 A8 BR112014015832 A8 BR 112014015832A8 BR 112014015832 A BR112014015832 A BR 112014015832A BR 112014015832 A BR112014015832 A BR 112014015832A BR 112014015832 A8 BR112014015832 A8 BR 112014015832A8
- Authority
- BR
- Brazil
- Prior art keywords
- halogen
- disorders
- hydrogen
- formula
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
resumo patente de invenção: "derivados heterocíclicos como receptores associados com aminas vistigiais (taars)". a presente invenção refere-se aos compostos da fórmula i, em que r1 é um grupo heteroarila de um ou dois membros, selecionado do grupo que consiste na fórmula (a), (b), (c), (d), (e), (f), (g), (h), (i) ou (j); r2 é hidrogênio ou halogênio; ou r1 e r2 podem formar junto com os átomos de carbono aos quais estão ligados os seguintes anéis da fórmula (k), (l), (m), (n) ou (o); r3 é hidrogênio, halogênio ou alquila inferior; n é 1 ou 2; r4 é fenila, opcionalmente substituída por um ou dois substituintes, selecionados de halogênio ou ciano, ou é piridinila, opcionalmente substituída por halogênio, ou é tetra-hidropirano, ou é -nh-c(o)-fenila, opcionalmente substituída por halogênio; r5 é hidrogênio ou halogênio; r6 - r13 são fenila, opcionalmente substituída por halogênio; r14 é -nh-c(o)-fenila, substituída por halogênio; r15 é hidrogênio, alquila inferior substituída por halogênio ou é halogênio; r16 é hidrogênio ou alcóxi inferior; r17 é piridinila, opcionalmente substituída por alcóxi inferior ou alquila inferior substituída por halogênio; ou a um sal farmaceuticamente de adição de ácido adequado dos mesmos, a todas as misturas racêmicas, a todos seus enantiômeros e/ou isômeros ópticos correspondentes e a todas formas tautoméricas dos compostos da fórmula i. os compostos da fórmula i têm uma afinidade boa pelos receptores associados a aminas vistigiais (taars), especialmente para taar1. os compostos podem ser usados para o tratamento de depressão, distúrbios de ansiedade, distúrbio bipolar, distúrbio de déficit de atenção-hiperatividade (adhd), distúrbios relacionados ao estresse, distúrbios psicóticos tais como esquizofrenia, doenças neurológicas tais como doença de parkinson, distúrbios neurodegenerativos tais como doença de alzheimer, epilepsia, enxaqueca, hipertensão, abuso de substância e distúrbios metabólicos tais como distúrbios alimentares, diabetes, complicações diabéticas, obesidade, dislipidemia, distúrbios de consumo e assimilação de energia, distúrbios e mau funcionamento da homeóstase da temperatura corporal, distúrbios do sono e ritmo circadiano, e distúrbios cardiovasculares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12150876 | 2012-01-12 | ||
PCT/EP2013/050170 WO2013104591A1 (en) | 2012-01-12 | 2013-01-08 | Heterocyclic derivatives as trace amine associated receptors (taars) |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014015832A2 BR112014015832A2 (pt) | 2017-06-13 |
BR112014015832A8 true BR112014015832A8 (pt) | 2017-07-04 |
Family
ID=47603607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014015832A BR112014015832A8 (pt) | 2012-01-12 | 2013-01-08 | derivados heterocíclicos como receptores associados com aminas vistigiais (taars) |
Country Status (14)
Country | Link |
---|---|
US (1) | US9181230B2 (pt) |
EP (1) | EP2802578B1 (pt) |
JP (1) | JP5872069B2 (pt) |
KR (1) | KR101631003B1 (pt) |
CN (1) | CN104024250B (pt) |
AR (1) | AR089691A1 (pt) |
BR (1) | BR112014015832A8 (pt) |
CA (1) | CA2856204A1 (pt) |
ES (1) | ES2554843T3 (pt) |
HK (1) | HK1196357A1 (pt) |
MX (1) | MX354815B (pt) |
RU (1) | RU2621050C2 (pt) |
TW (1) | TW201332998A (pt) |
WO (1) | WO2013104591A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
JP2015131783A (ja) * | 2014-01-14 | 2015-07-23 | 株式会社日本ファインケム | アリール−1,2,4−トリアゾール誘導体の製造方法 |
JP2019514960A (ja) * | 2016-05-04 | 2019-06-06 | パーデュー ファーマ エルピー | オキサゾリンシュードダイマー、医薬組成物及びその使用 |
KR102161787B1 (ko) * | 2018-07-02 | 2020-10-06 | 한국기초과학지원연구원 | 수면 장애의 예방 또는 치료용 약학적 조성물 |
WO2023033680A1 (en) | 2021-09-01 | 2023-03-09 | Limited Liability Company «Excellena Research And Development» (Llc «Excellena») | Substituted 2,3,4,5-tetrahydrobenzo[ f][1,4]oxazepines as modulators of trace amine-associated receptor 1 (taar1) |
WO2023033681A1 (en) | 2021-09-01 | 2023-03-09 | Limited Liability Company «Excellena Research And Development» (Llc «Excellena») | Substituted 2-(5-aryl-4 h-1,2,4-triazol-3-yl)ethanamines as modulators of trace amine-associated receptor 1 (taar1) |
WO2023033679A1 (en) | 2021-09-01 | 2023-03-09 | Limited Liability Company «Excellena Research And Development» (Llc «Excellena») | (azacycloalkyl)methoxy-substituted benzamides as modulators of trace amine-associated receptor 1 (taar1) |
CN114426494B (zh) * | 2022-01-13 | 2023-09-15 | 江苏海洋大学 | 一种具有作用于taar激动剂的取代甲胺类衍生物 |
CN115785019A (zh) * | 2022-12-07 | 2023-03-14 | 西安都创医药科技有限公司 | 一种乙基-1-氧-4-氮杂螺环[5.5]十一烷-9-羧酸乙酯的合成方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
GB9520150D0 (en) * | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
AU2002337498B2 (en) * | 2001-09-21 | 2006-08-10 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
AR064660A1 (es) * | 2006-12-26 | 2009-04-15 | Mitsubishi Tanabe Pharma Corp | Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras |
WO2008098857A1 (en) | 2007-02-15 | 2008-08-21 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
WO2009019149A1 (en) * | 2007-08-03 | 2009-02-12 | F. Hoffmann-La Roche Ag | Pyridinecarboxamide and benzamide derivatives as taar1 ligands |
CA2698818A1 (en) | 2007-09-14 | 2009-03-19 | Sanofi-Aventis | 3-methyl-2- ( (2s) -2- (4- (3-methyl-1, 2, 4-oxadiazol-5-yl) phenyl) morpholino) -6- (pyrimidin-4-yl) pyrimidin-4 (3h) -one as tau protein kinase inhibitor |
US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
TW201206893A (en) | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
US9132136B2 (en) | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
US8802673B2 (en) * | 2011-03-24 | 2014-08-12 | Hoffmann-La Roche Inc | Heterocyclic amine derivatives |
US9073911B2 (en) | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
US9029370B2 (en) * | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
-
2013
- 2013-01-08 RU RU2014132044A patent/RU2621050C2/ru not_active IP Right Cessation
- 2013-01-08 US US14/328,398 patent/US9181230B2/en not_active Expired - Fee Related
- 2013-01-08 JP JP2014551584A patent/JP5872069B2/ja not_active Expired - Fee Related
- 2013-01-08 MX MX2014008402A patent/MX354815B/es active IP Right Grant
- 2013-01-08 CA CA2856204A patent/CA2856204A1/en not_active Abandoned
- 2013-01-08 BR BR112014015832A patent/BR112014015832A8/pt not_active Application Discontinuation
- 2013-01-08 WO PCT/EP2013/050170 patent/WO2013104591A1/en active Application Filing
- 2013-01-08 CN CN201380004649.4A patent/CN104024250B/zh not_active Expired - Fee Related
- 2013-01-08 KR KR1020147022360A patent/KR101631003B1/ko active IP Right Grant
- 2013-01-08 EP EP13700984.1A patent/EP2802578B1/en not_active Not-in-force
- 2013-01-08 ES ES13700984.1T patent/ES2554843T3/es active Active
- 2013-01-09 AR ARP130100073A patent/AR089691A1/es unknown
- 2013-01-11 TW TW102101212A patent/TW201332998A/zh unknown
-
2014
- 2014-09-29 HK HK14109757.8A patent/HK1196357A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US9181230B2 (en) | 2015-11-10 |
CN104024250B (zh) | 2016-01-27 |
US20150045359A1 (en) | 2015-02-12 |
RU2621050C2 (ru) | 2017-05-31 |
JP5872069B2 (ja) | 2016-03-01 |
AR089691A1 (es) | 2014-09-10 |
ES2554843T3 (es) | 2015-12-23 |
MX354815B (es) | 2018-03-22 |
CN104024250A (zh) | 2014-09-03 |
KR101631003B1 (ko) | 2016-06-15 |
JP2015503600A (ja) | 2015-02-02 |
WO2013104591A1 (en) | 2013-07-18 |
CA2856204A1 (en) | 2013-07-18 |
RU2014132044A (ru) | 2016-03-10 |
KR20140116920A (ko) | 2014-10-06 |
MX2014008402A (es) | 2014-08-22 |
BR112014015832A2 (pt) | 2017-06-13 |
HK1196357A1 (zh) | 2014-12-12 |
TW201332998A (zh) | 2013-08-16 |
EP2802578B1 (en) | 2015-10-07 |
EP2802578A1 (en) | 2014-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014015832A8 (pt) | derivados heterocíclicos como receptores associados com aminas vistigiais (taars) | |
BR112013024312A2 (pt) | derivados de amina heterocíclica | |
BR112013031324A2 (pt) | derivados de pirazol | |
BR112012015168A2 (pt) | "derivados de benzamida substituída". | |
ECSP11010782A (es) | Derivados de 4,5-dihidro-oxazol-2-ilo | |
BR112013030698A2 (pt) | derivados de benzamida substituídas | |
MX2017001096A (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo. | |
BR112016005994A2 (pt) | derivados de etinila | |
BR112015001771A2 (pt) | derivados de carboxamida de triazol | |
MX2016013412A (es) | Derivados de morfolina-piridina. | |
MX2009005920A (es) | Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina. | |
PH12015500489A1 (en) | Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinsons disease | |
BR112013000253A2 (pt) | derivados de (3-metilpirrolidin-3-il) metil piridinil éter e seu uso como antagonistas do receptor nk-3 | |
BR112013010558A2 (pt) | derivados de di-hidro-oxazol-2-amina | |
MX2016012624A (es) | Derivados de 5-oxa-2-azabiciclo[2.2.2]octan-4-ilo y 5-oxa-2-azabiciclo[2.2.1]heptan-4-ilo como modularores de los receptores asociados a la amina de trazas 1 (taar1). | |
BR112015009990A2 (pt) | derivados de pirazina | |
MX2016016606A (es) | Derivados de 6-amino-5,6,7,8-tetrahidronaftalen-2-ilo o de 3-aminocroman-7-ilo como moduladores de receptores asociados a aminastraza (taar). | |
MX2016016190A (es) | Derivados de pirazino[2,1-a]isoquinolina sustituida para el tratamiento de trastornos del sistema nervioso central. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |